БОУМЕН Роберт А. (US),РИЧАРДСОН Питер (US),КОСТЕЛЛО Дональд (US),ЛЕОНЕ-БЭЙ Андреа (US)
申请号：
RU2012136221/15
公开号：
RU2012136221A
申请日:
2012.08.23
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method for delivering an active agent to a patient in need thereof, comprising: selection of the active substance is degraded in the body of said patient, wherein efficacy of said active substance decreases as a result of said degradation combining said active ingredient with a diketopiperazine to produce a pharmaceutical composition suitable for pulmonary inhalation and introducing said pharmaceutical composition to said patsientu.2. A method according to claim 1, wherein said degradation occurs in venous blood flow in peripheral tissue in the gastro-intestinal system or pecheni.3. A method according to claim 1, wherein said diketopiperazine is 2,5-diketo-3,6-di (4-X-aminobutyl) piperazine, wherein X is selected from the group consisting of succinyl, glutaryl, Male and fumaryl, or a pharmaceutically solyu.4 acceptable. The method of claim 1, wherein the pharmaceutical composition is a dry powder dosage form for ingalyatsii.5. A method according to claim 4, wherein said dry powder formulation for inhalation further comprises a pharmaceutically acceptable carrier or napolnitel.6. A method according to claim 4, wherein the dry powder formulation for inhalation administered to said patient by pulmonary inhalation using a dry inhalation system for poroshkom.7. A method according to claim 1, wherein the active substance is a protein, peptide or analogom.8. A method according to claim 1, wherein the active agent is an endocrine hormone or its analogom.9. A method according to claim 8, wherein the endocrine hormone is a hormone associated with diabetes, hyperglycemia and / or ozhireniem.10. A method according to claim 9,1. Способ доставки активного вещества пациенту, нуждающемуся в этом, включающий:выбор активного вещества, подвергающегося деградации в организме указанного пациента, где эффективность указанного активного вещества уменьшается в результате указанной деградацииобъединение указанного активного вещества с дикетопиперазином для получения фармацевтической ко
